TGF-β inducible early factor-1 (TIEF-1) and a method to detect breast cancer
AssigneeMayo Foundation for Medical Educational Research
InventorsMalayannan Subramaniam, Thomas C. Spelsberg, Patrick C. Roche
Life of this patent
Estimating the term…
Abstract
Methods to determine TIEF-1 polypeptide, or genetic rearrangements in the TIEF-1 gene, in a sample are provided. Also provided are TIEF-1 specific antibodies and nucleic acid probes, and methods of employing those antibodies and probes to detect breast cancer in situ in a mammalian tissue sample.
Claims9
An isolated peptide having an amino acid sequence corresponding to SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, or a variant thereof, which peptide, when administered to an animal, results in the production of antibodies that specifically bind to a polypeptide having an amino acid sequence consisting of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:5.
A method for detecting or determining the presence or amount of a mammalian polypeptide having SEQ ID NO:2 in a mammalian physiological sample, comprising:
- (a) contacting an amount of purified antibodies which specifically react with the polypeptide with the sample to be tested, for a sufficient time to allow the formation of binary complexes between at least a portion of the antibodies and at least a portion of the polypeptide in said sample;
- and
- (b) detecting or determining the presence or amount of said binary complexes.
A diagnostic method for monitoring the progression of breast cancer in a patient, comprising
- (a) contacting an amount of purified antibodies which specifically react with a human polypeptide having SEQ ID NO:2, with a sample comprising said polypeptide obtained from said patient, for a sufficient time to allow the formation of binary complexes between at least a portion of the antibodies and a portion of the polypeptide in said sample;
- (b) detecting or determining the presence or amount of said binary complexes;
- repeating steps (a) and (b) at a point later in time;
- and
- (d) comparing the result of step (b) with the result of step (c), wherein a decreased amount of said complexes at the later point in time is indicative of the progression of said cancer.
Dependencies are inferred from the claim text.